Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The blocking effect of zinc on complement factor H <i>in vitro</i>: further proof by the hemolytic assay of Pilar Sánchez-Corral.

Journal of immunoassay & immunochemistry·2023

Same author

The evaluation of some serum immunochemical markers in early onset pre-eclamptic women from Algeria.

American journal of reproductive immunology (New York, N.Y. : 1989)·2022

Same author

NLR: A Cost-effective Nomogram to Guide Therapeutic Interventions in COVID-19.

Immunological investigations·2020

Same author

Complementology's foundation: The 100-year anniversary of the Nobel Prize to Jules Bordet.

Journal of immunoassay & immunochemistry·2019

Same author

C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.

Journal of immunoassay & immunochemistry·2016

Search research articles

Related Experiment Video

Updated: Jan 3, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Semi-solid phase assay for the alternative complement pathway activity assessment (AP₁₀₀).

Kheir Eddine Kerboua¹, Kamal Djenouhat²

¹Laboratory of Immunology, Faculty of Medicine, University of Kasdi Merbah Ouargla, Algeria.

Journal of Immunoassay & Immunochemistry

|November 28, 2019

Summary

A new, affordable alternative pathway complement (APC) assay, AP100, is introduced to aid global clinical laboratories. This simple, reliable assay is crucial for monitoring expensive treatments like Eculizumab.

Keywords:

AP100 Alternative complement pathway low income countries medicine simple assay

More Related Videos

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Related Experiment Videos

Last Updated: Jan 3, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Area of Science:

Clinical Chemistry
Immunology
Complement System Assays

Background:

The alternative complement pathway (ACP) is implicated in various diseases, necessitating effective monitoring.
Eculizumab, a costly drug targeting ACP, requires reliable assays for patient management.
Current ACP assays like AH50 present challenges for many laboratories, especially in resource-limited settings.

Purpose of the Study:

To provide a detailed protocol for the standardized hemolytic assay AP100.
To enable clinical laboratories worldwide, particularly in developing countries, to perform ACP assays.
To offer a practical and affordable alternative to existing ACP diagnostic methods.

Main Methods:

Standardized hemolytic assay protocol (AP100) detailed.
Procedure similar to AP50 but with modified ACP buffer concentration and chicken erythrocyte density.
Focus on simplicity, portability, and ease of use for bedside and field applications.

Main Results:

AP100 assay is presented as a standardized, detailed protocol.
The assay demonstrates advantages over AH50, including reliability for Eculizumab monitoring.
AP100 is practical for storage and transport, remaining stable for weeks.

Conclusions:

AP100 offers a reliable, affordable, and practical solution for ACP assays globally.
The assay has at least nine clinical applications in disease diagnosis and follow-up.
AP100 facilitates improved patient care and treatment monitoring, especially for Eculizumab therapy.